Background Hyperkalemia poses a significant risk of sudden cardiac death, especially for those with end-stage renal diseases (ESRD). Smartwatches with ECG capabilities offer a promising solution for continuous, non-invasive monitoring using AI. Objectives To develop an AI-ECG algorithm to predict serum potassium level in ESRD patient with smartwatch generated ECG waveforms. Methods A cohort of 152,508 patients with 293,557 ECGs paired serum potassium levels obtained within one hour at Cedars Sinai Medical Center (CSMC) was used to train an AI-ECG model (‘Kardio-Net’) to predict serum potassium level. The model was further fine-tuned on 4,337 ECGs from 1,463 patients with ESRD using inputs from 12-lead and single-lead ECGs. Kardio-Net was evaluated in held-out test cohorts from CSMC and Stanford Healthcare (SHC) as well as a prospective international cohort of 40 ESRD patients with smartwatch ECGs at Chang Gung Memorial Hospital (CGMH). Results The Kardio-Net, when applied to 12-lead ECGs, identified severe hyperkalemia with an AUC of 0.852 and a mean absolute error (MAE) of 0.527 mEq/L. In external validation at SHC, the model achieved an AUC of 0.849 and an MAE of 0.599 mEq/L. For single-lead ECGs, Kardio-Net detected hyperkalemia with an AUC of 0.876 and had an MAE of 0.575 mEq/L in the CSMC test cohort. Using prospectively obtained smartwatch data, the AUC was 0.831, with an MAE of 0.580 mEq/L. Conclusions We validate a deep learning model to predict serum potassium levels from both 12-lead ECGs and single-lead smartwatch data, demonstrating its utility for remote monitoring of hyperkalemia. Condensed Abstract Hyperkalemia significantly increases the risk of sudden cardiac death in end-stage renal disease (ESRD) patients. We developed ‘Kardio-Net,’ an AI-driven ECG model, using data from 152,508 patients at Cedars Sinai Medical Center, and refined it with ECGs from 1,463 ESRD patients using inputs from 12-lead and single-lead ECGs. This model facilitates continuous and non-invasive potassium monitoring, leveraging both traditional and smartwatch-generated ECGs. Tested across various cohorts, including a prospective smartwatch group, Kardio-Net achieved an AUC range of 0.807 to 0.876, demonstrating its effectiveness for real-time hyperkalemia monitoring.
No takes yet. Share an insight, caveat, or question.
Chiu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: